Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies

Scandinavian Journal of Immunology

Volumn 84, Issue 2, 2016, Pages 100-109

  Ekholm, L ^a   Vosslamber, S ^b   Tjarnlund A ^a   de Jong, T D ^b   Betteridge, Z ^c   McHugh, N ^c   Plestilova, L ^d   Klein, M ^d   Padyukov, L ^a   Voskuyl, A E ^b   Bultink, I E M ^b   Michiel Pegtel, D ^b   Mavragani, C P ^e,f   Crow, M K ^e   Vencovsky, J ^d   Lundberg, I E ^a   Verweij, C L ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BATH   (United Kingdom)

^d INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMA AUTOANTIBODY; AUTOANTIBODY; EJ AUTOANTIBODY; IMMUNOMODULATING AGENT; INTERFERON; JO 1 ANTIBODY; KS AUTOANTIBODY; KU AUTOANTIBODY; LA ANTIBODY; MDA5 AUTOANTIBODY; MI 2 AUTOANTIBODY; NEUTRALIZING ANTIBODY; NXP2 AUTOANTIBODY; OJ AUTOANTIBODY; PL12 AUTOANTIBODY; PL7 AUTOANTIBODY; PM SCL AUTOANTIBODY; PREDNISOLONE; RNAPI AUTOANTIBODY; RNAPII AUTOANTIBODY; RNAPIII AUTOANTIBODY; RO60 AUTOANTIBODY; SAE AUTOANTIBODY; SRP AUTOANTIBODY; TIF1 GAMMA AUTOANTIBODY; TOPO AUTOANTIBODY; U1RNP AUTOANTIBODY; U3RNP AUTOANTIBODY; UNCLASSIFIED DRUG; ZO AUTOANTIBODY;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; BLOOD; CONTROLLED STUDY; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOASSAY; IMMUNOPRECIPITATION; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84978880621     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12449     Document Type: Article

References (46)

1. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 2004;18:331–44.
2. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527–35.
3. Hengstman GJ, Brouwer R, Egberts WT, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69–75.
4. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000;12:475–81.
5. Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A 1990;87:9933–7.
6. Higgs BW, Liu Z, White B et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029–36.
7. Greenberg SA. Inflammatory myopathies: disease mechanisms. Curr Opin Neurol 2009;22:516–23.
8. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664–78.
9. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59–68.
10. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436–46.
11. Krol P, Krystufkova O, Polanska M, et al. Serum levels of interferon alpha do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis 2011;70:879–80.
12. Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784–92.
13. Bave U, Vallin H, Alm GV, Ronnblom L. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001;17:71–80.
14. Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999;163:6306–13.
15. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861–72.
16. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006;54:1917–27.
17. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112–24.
18. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403–7.
20. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705–13.
21. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43:49–54.
22. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281–90.
23. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004;63:297–301.
24. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007;46:1005–8.
25. Ghirardello A, Rampudda M, Ekholm L, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010;49:2370–4.
26. van Baarsen LG, Vosslamber S, Tijssen M, et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008;3:e1927.
27. Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73:256–62.
28. Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R95.
29. Vosslamber S, Raterman HG, van der Pouw Kraan TC, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011;70:1153–9.
30. de Jong TD, Vosslamber S, Mantel E, et al. Physiological evidence for diversification of IFNalpha- and IFNbeta-mediated response programs in different autoimmune diseases. Arthritis Res Ther 2016;18:49.
31. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225–35.
32. Crow MK. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol 2014;26:467–74.
33. Greenberg SA, Higgs BW, Morehouse C, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012;13:207–13.
34. Shiba H, Takeuchi T, Isoda K, et al. Dermatomyositis as a complication of interferon-alpha therapy: a case report and review of the literature. Rheumatol Int 2014;34: 1319–1322.
35. Balboni I, Niewold TB, Morgan G, et al. Interferon-alpha induction and detection of anti-Ro, anti-La, anti-Sm, and anti-RNP autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum 2013;65:2424–9.
36. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011;116:227–37.
37. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013;25:248–53.
38. Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 2015;64:125–36.
39. Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012;7:e29161.
40. McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol 2008;35:452–6.
41. Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011;70:831–6.
42. Flammer JR, Dobrovolna J, Kennedy MA, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 2010;30:4564–74.
43. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009;60:1815–24.
44. Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol 2014;192:5459–68.
45. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;182:34–8.
46. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905–13.